$6.79
0.44% yesterday
Nasdaq, Jul 05, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

MiMedx Group, Inc. Target price 2024 - Analyst rating & recommendation

MiMedx Group, Inc. Classifications & Recommendation:

Buy
100%

MiMedx Group, Inc. Price Target

Target Price $12.43
Price $6.79
Potential
Number of Estimates 7
7 Analysts have issued a price target MiMedx Group, Inc. 2025 . The average MiMedx Group, Inc. target price is $12.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 6 Analysts recommend MiMedx Group, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the MiMedx Group, Inc. stock has an average upside potential 2025 of . Most analysts recommend the MiMedx Group, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 321.48 360.24
20.03% 12.06%
EBITDA Margin 12.61% 22.11%
271.71% 75.33%
Net Margin 14.69% 12.52%
180.79% 14.74%

7 Analysts have issued a sales forecast MiMedx Group, Inc. 2024 . The average MiMedx Group, Inc. sales estimate is

$360m
Unlock
. This is
7.69% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$365m 9.20%
Unlock
, the lowest is
$350m 4.66%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $321m 20.03%
2024
$360m 12.06%
Unlock
2025
$407m 12.90%
Unlock
2026
$471m 15.84%
Unlock
2027
$487m 3.37%
Unlock
2028
$554m 13.73%
Unlock

3 Analysts have issued an MiMedx Group, Inc. EBITDA forecast 2024. The average MiMedx Group, Inc. EBITDA estimate is

$79.6m
Unlock
. This is
61.20% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$81.7m 65.38%
Unlock
, the lowest is
$76.0m 53.85%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $40.5m 306.10%
2024
$79.6m 96.43%
Unlock
2025
$89.8m 12.73%
Unlock
2026
$108m 19.87%
Unlock

EBITDA Margin

2023 12.61% 271.71%
2024
22.11% 75.33%
Unlock
2025
22.07% 0.18%
Unlock
2026
22.84% 3.49%
Unlock

7 MiMedx Group, Inc. Analysts have issued a net profit forecast 2024. The average MiMedx Group, Inc. net profit estimate is

$45.1m
Unlock
. This is
33.54% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$54.6m 19.56%
Unlock
, the lowest is
$36.9m 45.66%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $47.2m 196.97%
2024
$45.1m 4.47%
Unlock
2025
$60.3m 33.66%
Unlock
2026
$92.2m 52.97%
Unlock
2027
$97.4m 5.60%
Unlock
2028
$133m 36.37%
Unlock

Net Margin

2023 14.69% 180.79%
2024
12.52% 14.74%
Unlock
2025
14.82% 18.37%
Unlock
2026
19.57% 32.05%
Unlock
2027
19.99% 2.15%
Unlock
2028
23.97% 19.91%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 0.32 0.31
196.97% 3.13%
P/E 22.21
EV/Sales 2.70

7 Analysts have issued a MiMedx Group, Inc. forecast for earnings per share. The average MiMedx Group, Inc. <a href=/blog/eps>EPS is

$0.31
Unlock
. This is
32.61% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$0.37 19.57%
Unlock
, the lowest is
$0.25 45.65%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $0.32 196.97%
2024
$0.31 3.13%
Unlock
2025
$0.41 32.26%
Unlock
2026
$0.63 53.66%
Unlock
2027
$0.66 4.76%
Unlock
2028
$0.90 36.36%
Unlock

P/E ratio

Current 14.62 150.73%
2024
22.21 51.92%
Unlock
2025
16.62 25.17%
Unlock
2026
10.86 34.66%
Unlock
2027
10.29 5.25%
Unlock
2028
7.54 26.72%
Unlock

Based on analysts' sales estimates for 2024, the MiMedx Group, Inc. stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.91 3.32%
2024
2.70 7.16%
Unlock
2025
2.39 11.43%
Unlock
2026
2.07 13.67%
Unlock
2027
2.00 3.26%
Unlock
2028
1.76 12.08%
Unlock

P/S ratio

Current 3.00 10.03%
2024
2.78 7.14%
Unlock
2025
2.46 11.43%
Unlock
2026
2.13 13.68%
Unlock
2027
2.06 3.26%
Unlock
2028
1.81 12.08%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today